drugset / Trial / NCT07460245
Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study represents an innovative opportunity in the treatment of metastatic urothelial carcinoma
Timeline
- Start
- 2026-06
- Primary completion
- 2026-06
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 800 mg | Intravenous |